What is the recommended treatment for Candida glabrata vaginal infection in an 88-year-old woman with a pessary (treated with boric acid) who has completed a 14- to 24-day course of nystatin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment for Candida glabrata After Failed Nystatin Therapy

Since nystatin has already failed after 14-24 days of treatment, the next step is intravaginal boric acid 600 mg daily for 14 days, which is the recommended first-line therapy for C. glabrata vulvovaginitis unresponsive to azoles and nystatin. 1

Clinical Context and Reasoning

This 88-year-old patient with a pessary represents a complicated vulvovaginal candidiasis case due to:

  • Non-albicans species (C. glabrata)
  • Presence of foreign body (pessary)
  • Failed initial therapy with nystatin
  • Advanced age

C. glabrata accounts for 10-20% of recurrent vulvovaginal candidiasis cases and is inherently less susceptible to conventional azole therapies compared to C. albicans 2, 1. The pessary creates a persistent nidus for infection and biofilm formation.

Treatment Algorithm After Nystatin Failure

First-Line: Boric Acid

  • Intravaginal boric acid 600 mg in gelatin capsule daily for 14 days 1
  • Clinical and mycologic eradication rates: approximately 70% 2
  • Must be compounded by pharmacy
  • Studies show 64-71% success in symptomatic women with C. glabrata 3
  • Critical caveat: Boric acid is toxic if ingested; counsel patient on proper vaginal administration only

Second-Line Options if Boric Acid Fails

  1. Topical 17% flucytosine cream (alone or combined with 3% amphotericin B cream) daily for 14 days 1

    • Requires compounding by pharmacy
    • Success rate approximately 90% in azole-refractory cases 3
    • Weak recommendation due to limited data 1
  2. Repeat nystatin course - Though already attempted, the guidelines list nystatin intravaginal suppositories 100,000 units daily for 14 days as an alternative 1. However, given prior failure, this is less advisable.

Essential Concurrent Management

Pessary Management

  • Remove and clean pessary during treatment - The pessary must be disinfected or temporarily removed during antifungal therapy to eliminate the biofilm reservoir
  • Consider pessary removal schedule that allows vaginal tissue recovery
  • Evaluate if pessary is still medically necessary

Confirm Diagnosis

  • Obtain vaginal culture to confirm C. glabrata and rule out mixed infection 1
  • Consider antifungal susceptibility testing given treatment failure 1
  • Wet mount with KOH to confirm active infection vs. colonization 1

Important Clinical Pitfalls

Do not use oral fluconazole - C. glabrata has reduced susceptibility to all azoles, including fluconazole and voriconazole 1, 4. Therapy with azoles is "frequently unsuccessful" for C. glabrata 1, 4.

Distinguish infection from colonization - The most critical decision is whether C. glabrata represents true infection requiring treatment versus colonization in a patient with other pathology 1. Only treat if symptomatic with confirmed yeast on microscopy.

Age considerations - At 88 years old, this patient may have vaginal atrophy contributing to symptoms. Ensure symptoms are truly from candidiasis and not atrophic vaginitis.

If Recurrence Occurs

For recurring C. glabrata infection after successful treatment:

  • Consider maintenance therapy with boric acid (dosing frequency not well-established in guidelines, but expert consensus suggests 1-3 times weekly) 5
  • Re-evaluate pessary necessity and fit
  • Screen for diabetes, immunosuppression, or other predisposing factors
  • Some experts use individualized degressive regimens to find the lowest effective maintenance dose 6

Contraindications and Safety

Boric acid should not be used during pregnancy 5. At age 88, pregnancy is not a concern. Local side effects are uncommon with boric acid 3, 7. The patient should be counseled that boric acid is for vaginal use only and is toxic if swallowed.

Related Questions

What is the recommended dose of boric acid for treating a vaginal Candida glabrata infection resistant to azole therapy?
Can boric acid be used to treat Candida albicans vulvovaginitis in a patient who has failed three oral fluconazole 150 mg doses given every three days?
How should intravaginal boric acid be used to treat fluconazole‑resistant vulvovaginal candidiasis in a woman?
Can an adult female with Candida glabrata vulvovaginal infection who is also being treated with penicillin for Streptococcus agalactiae (group B streptococcus) safely use intravaginal boric acid?
Is boric acid effective for treating Candida glabrata infections?
What does a normal middle cerebral artery (MCA) Doppler velocimetry result indicate and how should it be managed?
Which direction of shoulder range of motion is most severely limited in adhesive capsulitis (frozen shoulder)?
In patients with chronic kidney disease, what are the indications, dosing, and monitoring recommendations for calcium supplementation and calcitriol (active vitamin D) therapy?
For a patient with chronic kidney disease, at what serum bicarbonate level should oral sodium bicarbonate be initiated, what dosing and monitoring are recommended, and when should sevelamer carbonate be started for hyperphosphatemia, including its dosing and monitoring guidelines?
What are the medication interaction risks for a patient on losartan, metformin, diltiazem, escitalopram (Lexapro), cyclobenzaprine, and dabigatran?
What are the normal uterine artery Doppler indices in a healthy pregnant woman?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.